Galvus Met 50mg/1000mg Tablet is a combination oral antidiabetic medication containing Metformin 1000mg and Vildagliptin 50mg, designed to improve glycemic control in adults with type 2 diabetes mellitus. Metformin, a biguanide, primarily works by decreasing hepatic glucose production and enhancing insulin sensitivity in peripheral tissues, thereby reducing blood sugar levels. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. This dual mechanism addresses both insulin resistance and impaired insulin secretion, making Galvus Met effective for patients inadequately controlled on either agent alone or on diet and exercise. It is typically prescribed alongside lifestyle modifications such as diet and physical activity. The combination therapy helps reduce fasting and postprandial blood glucose levels, contributing to better overall glycemic management and lowering the risk of diabetes-related complications. Patients should take the tablet as directed by a healthcare professional, usually with meals to minimize gastrointestinal side effects. Regular monitoring of blood glucose and renal function is recommended during treatment. Galvus Met is not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment.